Lung‐Yi Mak

5.0k total citations · 1 hit paper
164 papers, 3.2k citations indexed

About

Lung‐Yi Mak is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Lung‐Yi Mak has authored 164 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Epidemiology, 108 papers in Hepatology and 20 papers in Molecular Biology. Recurrent topics in Lung‐Yi Mak's work include Hepatitis B Virus Studies (106 papers), Liver Disease Diagnosis and Treatment (97 papers) and Hepatitis C virus research (92 papers). Lung‐Yi Mak is often cited by papers focused on Hepatitis B Virus Studies (106 papers), Liver Disease Diagnosis and Treatment (97 papers) and Hepatitis C virus research (92 papers). Lung‐Yi Mak collaborates with scholars based in Hong Kong, China and United States. Lung‐Yi Mak's co-authors include Man‐Fung Yuen, Wai‐Kay Seto, James Fung, Ka Shing Cheung, Danny Ka‐Ho Wong, Ching‐Lung Lai, Rex Wan‐Hin Hui, M. Lynch, W. Michael O’Guin and Tung‐Tien Sun and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Cell Biology and Hepatology.

In The Last Decade

Lung‐Yi Mak

154 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions

2024 55 citations Lung‐Yi Mak, Ken Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lung‐Yi Mak Hong Kong	31	2.3k	1.8k	509	254	249	164	3.2k
Jessica Liu United States	24	1.1k 0.5×	876 0.5×	450 0.9×	157 0.6×	53 0.2×	48	2.1k
Luciano Tarantino Italy	28	844 0.4×	1.0k 0.6×	184 0.4×	155 0.6×	50 0.2×	69	2.0k
V. Desmet Belgium	28	1.3k 0.6×	1.3k 0.7×	322 0.6×	532 2.1×	135 0.5×	68	3.0k
Wen‐Yu Chang Taiwan	28	2.1k 0.9×	2.2k 1.2×	227 0.4×	207 0.8×	46 0.2×	86	2.8k
Shogo Ohkoshi Japan	15	1.4k 0.6×	1.7k 0.9×	376 0.7×	148 0.6×	41 0.2×	45	2.2k
Jeong Heo South Korea	35	1.2k 0.5×	1.6k 0.9×	633 1.2×	946 3.7×	43 0.2×	188	3.9k
Hendrik W. Reesink Netherlands	31	3.4k 1.5×	3.8k 2.1×	1.6k 3.1×	130 0.5×	32 0.1×	95	6.5k
Hans Dieter Nischalke Germany	32	1.3k 0.6×	1.4k 0.8×	322 0.6×	254 1.0×	93 0.4×	91	2.8k
Kazuaki Inoue Japan	28	1.1k 0.5×	1.1k 0.6×	686 1.3×	504 2.0×	56 0.2×	107	2.8k
Michèle Chevallier France	22	1.8k 0.8×	1.8k 1.0×	295 0.6×	144 0.6×	61 0.2×	41	2.6k

Countries citing papers authored by Lung‐Yi Mak

Since Specialization

Citations

This map shows the geographic impact of Lung‐Yi Mak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lung‐Yi Mak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lung‐Yi Mak more than expected).

Fields of papers citing papers by Lung‐Yi Mak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lung‐Yi Mak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lung‐Yi Mak. The network helps show where Lung‐Yi Mak may publish in the future.

Co-authorship network of co-authors of Lung‐Yi Mak

This figure shows the co-authorship network connecting the top 25 collaborators of Lung‐Yi Mak. A scholar is included among the top collaborators of Lung‐Yi Mak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lung‐Yi Mak. Lung‐Yi Mak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hui, Rex Wan‐Hin, et al.. (2025). Development and Validation of a High‐Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection. Journal of Viral Hepatitis. 32(4). e70023–e70023. 3 indexed citations

Mak, Lung‐Yi, Jimmy Che‐To Lai, Ken Liu, et al.. (2025). Chronic Hepatitis B Infection: Patient Guidance. Journal of Gastroenterology and Hepatology. 41(1). 61–77.

Hui, Rex Wan‐Hin, et al.. (2024). Investigational RNA Interference Agents for Hepatitis B. BioDrugs. 39(1). 21–32. 5 indexed citations

Hui, Rex Wan‐Hin, K.W. Chiu, Ho Ming Cheng, et al.. (2024). Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery. Hepatology. 82(2). 344–356. 1 indexed citations

Zhang, Saisai, Lung‐Yi Mak, Man‐Fung Yuen, & Wai‐Kay Seto. (2024). Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B. Clinical and Molecular Hepatology. 31(Suppl). S182–S195. 7 indexed citations

Mak, Lung‐Yi, Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, et al.. (2024). Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test. Journal of Gastroenterology and Hepatology. 39(12). 2826–2834. 6 indexed citations

Cheung, Ka Shing, Lung‐Yi Mak, Chi‐Ho Lee, et al.. (2024). Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes. Alimentary Pharmacology & Therapeutics. 60(10). 1398–1408. 6 indexed citations

Wong, Danny Ka‐Ho, et al.. (2023). Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study. BMC Gastroenterology. 23(1). 348–348. 6 indexed citations

Wei, E. P., Iris Y. Zhou, Man‐Fung Yuen, et al.. (2023). Portable electrical impedance tomography (EIT) system stages non-alcoholic fatty liver disease for potential screening and monitoring at home. PubMed. 2023. 1–4. 2 indexed citations

10.

Wong, Samuel W. K., Sze Keong Tey, Xiaowen Mao, et al.. (2023). Small Extracellular Vesicle‐Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma. Advanced Science. 10(26). e2302677–e2302677. 19 indexed citations

11.

Zhang, Saisai, Lung‐Yi Mak, Man‐Fung Yuen, & Wai‐Kay Seto. (2022). Screening strategy for non-alcoholic fatty liver disease. Clinical and Molecular Hepatology. 29(Suppl). S103–S122. 20 indexed citations

12.

Mak, Lung‐Yi, Danny Wong, Alison Kuchta, et al.. (2022). Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clinical and Molecular Hepatology. 29(1). 146–162. 15 indexed citations

13.

Zhang, Saisai, Hein M. Tun, Dengwei Zhang, et al.. (2022). Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. Frontiers in Microbiology. 13. 813783–813783. 6 indexed citations

14.

Mak, Lung‐Yi, Rex Wan‐Hin Hui, James Fung, et al.. (2021). Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatology International. 15(4). 901–911. 30 indexed citations

15.

Mak, Lung‐Yi, Rex Wan‐Hin Hui, James Fung, et al.. (2020). Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. Journal of Hepatology. 73(4). 800–806. 92 indexed citations

16.

Mak, Lung‐Yi, Michael Ko, Wai‐Pan To, et al.. (2019). Serum Mac‐2‐binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir‐treated chronic hepatitis B patients. Journal of Gastroenterology and Hepatology. 34(10). 1817–1823. 14 indexed citations

17.

Mak, Lung‐Yi, Wai‐Kay Seto, & Man‐Fung Yuen. (2019). Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. Current Hepatology Reports. 18(4). 503–511. 5 indexed citations

18.

Mak, Lung‐Yi, Chi‐Ho Lee, Ka Shing Cheung, et al.. (2019). Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long‐term nucleoside analogue. Liver International. 39(7). 1217–1225. 15 indexed citations

19.

Fung, James, Lung‐Yi Mak, Albert Chan, et al.. (2019). Model for End‐Stage Liver Disease With Additional Criteria to Predict Short‐Term Mortality in Severe Flares of Chronic Hepatitis B. Hepatology. 72(3). 818–828. 8 indexed citations

20.

Seto, Wai‐Kay, James Fung, Ka Shing Cheung, et al.. (2016). Body‐mass index is associated with fibrosis regression during long‐term nucleoside analogue therapy in chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 44(10). 1071–1079. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact